dc.creator | Herrera-Hidalgo, Laura | es |
dc.creator | Alarcón, Arístides de | es |
dc.creator | López-Cortes, Luís E. | es |
dc.creator | Luque-Márquez, Rafael | es |
dc.creator | López Cortés, Luis Fernando | es |
dc.creator | Gutiérrez Valencia, Alicia | es |
dc.creator | Gil Navarro, María Victoria | es |
dc.date.accessioned | 2020-11-26T18:38:41Z | |
dc.date.available | 2020-11-26T18:38:41Z | |
dc.date.issued | 2020-09-30 | |
dc.identifier.citation | Herrera-Hidalgo, L., De Alarcón, A., López-Cortes, L.E., Luque-Márquez, R., López Cortés, L.F., Gutiérrez Valencia, A. y Gil Navarro, M.V. (2020). Enterococcus faecalis Endocarditis and Outpatient Treatment: A Systematic Review of Current Alternatives. Antibiotics, 9 (10) | |
dc.identifier.issn | 2079-6382 | es |
dc.identifier.uri | https://hdl.handle.net/11441/102757 | |
dc.description.abstract | The selection of the best alternative for Enterococcus faecalis infective endocarditis (IE)
continuation treatment in the outpatient setting is still challenging. Three databases were searched,
reporting antibiotic therapies against E. faecalis IE in or suitable for the outpatient setting. Articles
the results of which were identified by species and treatment regimen were included. The quality of
the studies was assessed accordingly with the study design. Data were extracted and synthesized
narratively. In total, 18 studies were included. The treatment regimens reported were classified
regarding the main antibiotic used as regimen, based on Aminoglycosides, dual β-lactam, teicoplanin,
daptomycin or dalbavancin or oral therapy. The regimens based on aminoglycosides and dual
β-lactam combinations are the treatment alternatives which gather more evidence regarding their
efficacy. Dual β-lactam is the preferred option for high level aminoglycoside resistance strains,
and for to its reduced nephrotoxicity, while its adaptation to the outpatient setting has been poorly
documented. Less evidence supports the remaining alternatives, but many of them have been
successfully adapted to outpatient care. Teicoplanin and dalbavancin as well as oral therapy seem
promising. Our work provides an extensive examination of the potential alternatives to E. faecalis
IE useful for outpatient care. However, the insufficient evidence hampers the attempt to give a
general recommendation. | es |
dc.format | application/pdf | es |
dc.format.extent | 17 | es |
dc.language.iso | eng | es |
dc.publisher | MDPI | es |
dc.relation.ispartof | Antibiotics | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Enterococcus faecalis | es |
dc.subject | Infective endocarditis | es |
dc.subject | Outpatient treatment | es |
dc.subject | Outpatient parenteral antibiotic treatment | es |
dc.subject | OPAT | es |
dc.subject | Systematic review | es |
dc.subject | Treatment alternatives | es |
dc.title | Enterococcus faecalis Endocarditis and Outpatient Treatment: A Systematic Review of Current Alternatives | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.publisherversion | https://doi.org/10.3390/antibiotics9100657 | es |
dc.identifier.doi | 10.3390/antibiotics9100657 | es |
dc.journaltitle | Antibiotics | es |
dc.publication.volumen | 9 | es |
dc.publication.issue | 10 | es |